Title:
A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)(VAYHIT1)
Indication:
Thrombocytopenia
Location:
Texas Oncology-McAllen
Phase: III
Title:
Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)
Indication:
Breast Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)
Indication:
Breast Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Indication:
Lung Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Indication:
Lung Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 study of standard endocrine therapy with breast cancer
View
Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)
Indication:
Breast Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 study of standard endocrine therapy with breast cancer
View
Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 study of standard endocrine therapy with breast cancer
View
Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)
Indication:
Breast Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 Selin P53 Endo Carcinoma
View
Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 Selin P53 Endo Carcinoma
View
Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)
Indication:
Endometrial Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 Selin P53 Endo Carcinoma
View
Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer
View
Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)
Indication:
Lung Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer
View
Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer
View
Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)
Indication:
Lung Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
View
Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
View
Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
View
Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma
View
Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)
Indication:
Melanoma
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma
View
Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)
Indication:
Melanoma
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma
View
Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)
Indication:
Melanoma
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer
View
Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer
View
Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)
Indication:
Ovarian Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer
View
Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Weslaco
Phase: III